Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02537561
• Other study ID #: 15-x279
• Status: Withdrawn
• Phase: Phase 1
• First received: August 28, 2015
• Last updated: February 10, 2016
• Start date: December 2015
• Est. completion date: December 2018

Study information

• Verified date: February 2016
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

In this proposed study the investigators will combine gemcitabine and cisplatin with talazoparib to determine the recommended Phase 2 dose (RP2D) of this combination regimen. After determination of the RP2D patients with lung cancer whose tumors carry molecular alterations in DNA repair pathway genes will be enrolled to an expansion cohort to determine anti-tumor efficacy. Tissue samples of patients with confirmed partial response, complete response, and non-responders will be obtained for whole exome, and transcriptome sequencing to characterize the genetic alterations associated with response to therapy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of advanced solid tumor for which no curative standard treatment options exist and for which gemcitabine and cisplatin is a suitable treatment regimen.

• After the determination of the maximum tolerated dose, an expansion cohort of 20 patients with non-small cell lung cancer whose tumors demonstrate variants in DNA repair pathway genes will be enrolled.

• Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with CT scan, as = 20 mm by chest x-ray, or = 10 mm with calipers by clinical exam.

• Prior treatment for this disease is allowed if it has been completed at least 2 weeks prior to study enrollment and if all treatment-related toxicities are resolved. Prior exposure to a PARP inhibitor is allowed for patients in the dose-finding portion of the study.

• At least 18 years of age.

• ECOG performance status = 1

• Normal bone marrow and organ function as defined below:

• Leukocytes = 3,000/mcL

• Absolute neutrophil count = 1,500/mcl

• Platelets = 100,000/mcl

• Total bilirubin = 1.5 x IULN

• AST(SGOT)/ALT(SGPT) = 3.0 x IULN

• Creatinine = IULN OR creatinine clearance = 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

• Tissue available for sequencing (either archival tissue or readily accessible tumor for fresh routine biopsy).

• Able to swallow tablets.

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• A history of other malignancy = 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.

• Received any other investigational agent within 2 weeks of starting the first dose on study.

• Symptomatic brain metastases. Known brain metastases are allowed if asymptomatic and previously treated. Patients must be at least 4 weeks post-brain radiation therapy.

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, gemcitabine, talazoparib, or other agents used in the study.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active coronary artery disease, uncontrolled seizure, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.

• Known HIV-positivity.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Non-Small Cell Lung
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer
• Non-Small-Cell Lung Carcinoma
• Nonsmall Cell Lung Cancer
• Solid Tumors

Intervention

Drug:
• Cisplatin

• Gemcitabine

• Talazoparib

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	BioMarin Pharmaceutical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and toxicities as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0		30 days after completion of treatment (estimated average to be 7 months)	Yes
Primary	Maximum tolerated dose (MTD)	The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 30% of patients in a cohort are expected to experience a dose-limiting toxicity (DLT) during the second cycle based on the CRM algorithm. Dose escalations will proceed until the MTD is determined.	Completion of dose escalation portion of study (approximately 12 months)	Yes
Primary	Objective response rate (ORR) in preselected patients with BRCAness tumoral genotype	ORR - proportion of patients who achieved a complete response or a partial response	Up to completion of treatment (estimated average of 6 months)	No
Secondary	Disease control rate (DCR)	DCR - percentage of participants who have achieved complete response, partial response, and stable disease; Complete response: disappearance of all lesions and normalization of tumor marker level; Partial response: at least a 30% decrease in the sum of the diameters of target lesions and no new lesions; Stable disease: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease	Until death (estimated average to be 12 months)	No
Secondary	Progression-free survival (PFS)	PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.; -Progressive disease - At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, appearance of one more new lesions PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.	Until death (estimated average to be 12 months)	No
Secondary	Objective response rate (ORR)	ORR - proportion of patients who achieved a complete response or a partial response	Up to completion of treatment (estimated average of 6 months)	No
Secondary	Overall survival (OS)	OS: duration of time from start of treatment to time of death from any cause	Until death (estimated average to be 12 months)	No

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine